Screener
Tarsus Pharmaceuticals, Inc. TARS Business Segments — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOther.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other reconciling items(1) | 1,357 | 1,844 | 512 | 3,004 |
| Net loss | $(18,551) | $(20,340) | $(25,518) | $(45,460) |
| Other segment disclosures: | ||||
| Interest income | $3,698 | $4,229 | $7,420 | $7,683 |
| Interest expense | $(2,156) | $(2,240) | $(4,284) | $(4,453) |
| Depreciation and amortization expense | $(1,000) | $(453) | $(1,437) | $(913) |
| Provision for income taxes | $(2,716) | — | $(5,068) | — |
| (1) Other reconciling items primarily includes interest income, gain on exchange of long-term investments, interest expense, and provision for income taxes. |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s business segments — interest income?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — interest income of $3.7M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — interest income changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — interest income decreased by 12.6% year-over-year, from $4.23M to $3.7M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — interest income?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — interest income has grown at a 65.1% compound annual growth rate (CAGR), from $3.5M to $15.75M.
- What does business segments — interest income mean?
- Reflects the income generated from cash balances, short-term investments, and other interest-bearing assets held by the company. This provides insight into the company's liquidity management and the return on its capital reserves.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude